Referent:innen

Dr. Sven Deutschmann

Dr. Sven Deutschmann

Roche Diagnostics

Dr. Christoph Höppner

Dr. Christoph Höppner

Eurofins Biopharma Product Testing

Nicole Klüh

Nicole Klüh

Labor LS

Dr. Marja Claassen

Dr. Marja Claassen

MSD

Dr. Radhakrishna Tirumalai

Dr. Radhakrishna Tirumalai

MSD

Dr. Sebastian Thölken

Dr. Sebastian Thölken

Lonza

Dr. Holger Kavermann

Dr. Holger Kavermann

Roche Diagnostics

All times mentioned are CEST.

Zielsetzung

During this Live Online Training, the following contents and questions should be addressed by presentations and panel discussions.  Considering that, panelists from the fields Non-Sterile Products, Sterile Products, Combination Products as well as biopharmaceutical APIs and HCT/Ps will on hand for the training.

Hintergrund

In their Pharmacopeial Forum 39(4) in 2014, the USP published the draft of chapter <1115> “Bioburden Control of Nonsterile Drug Substances and Products”. The document outlines a risk-based approach to the control of potential contamination in non-sterile product manufacturing.

But “bioburden” is not only a topic of non-sterile products. Annex 1 of the European GMP Guideline requires “The bioburden should be monitored before sterilisation. There should be working limits on contamination immediately before sterilisation, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled product and terminally sterilised products.”

And last but not least, bioburden testing for medical devices made or used in the USA is governed by Title 21 of the Code of Federal Regulations and worldwide by ISO 11737.

The current developments determine us to address this topic in a special workshop session to look at this from various angles and provide you with information about the regulatory background and practical examples and strategies for bioburden control. Pharmacopoeial experts, representatives of pharmaceutical quality control and from testing laboratory will show you what are the challenges of the bioburden control strategy and how they implemented an adequate control in their companies.

Zielgruppe

This Live Online Training is of interest to professionals in microbiology from
  •  Pharmaceuticals and Biopharmaceutical Companies
  •  Academic Research Institutions
  •  Government Agencies
  •  Contract Service laboratories
who are involved in
  •  Research and Development
  •  Validation
  •  Microbiological QA and QC

Technical Requirements

We use WebEx for our live online training courses and webinars. At https://www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our trainings and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Programm

Bioburden - Live Online Training

Gesamtes Programm als PDF herunterladen

General Information
  • Bioburden control strategy dependent of the lifecycle phase of the product (so-called “Phase-appropriate control strategy”)
    - Early clinical Phase
    - Late clinical hase
    - Commercial phase
  •  Test for “specified microorganisms” and / or “objectionable microorganisms”?
    - Raw materials
    - In-process-control samples
    - Drug substance
    - Drug product
    - Final product
  •  Refresher on biofilms including case studies
    - Biofilm biology
    - How to recognize biofilms in bioburden Trends
    - Lessons learned from a company
Testing
  • Where is bioburden tested in processes?
  • Predefinition of  bioburden and / or endotoxins levels for raw materials
  • Assessment of  the presence / absence of “objectionable microorganisms” in your raw materials ?
  • What are the methods in use ?
    - TAMC
    - TYMC
    - MPN
    - Any other bioburden testing method
    - Rapid micro methods
  • Is it necessary to  have a limited shelf life for bioburden samples?
  • How to treat so called “missing bioburden” results ?
Limits
  • Predefined bioburden and / or endotoxins levels for your upstream / fermentation processes (if applicable) and downstream processes or for the whole process
  • What will be preferred? A two-tiered-control system (warning and alert level) or a three-tiered control system (warning and alert level AND rejection level)?
  • Methodologies in use to define the limits, e.g.
    • how many data points are required to define the limits
    • philosophy for new processes / new manufacturing processes without having experience of process capabilities
Deviation Management
  • Do you perform ID? If YES, when:
    - Each Colony
    - Only in case of an excursion of limits / level
  • What’s the preferred ID technique?
  • Measures in case of an excursion of a Limit
USP <1115>, USP<1229.3> and USP <1119>
  • Bioburden control of non-sterile drug substances and products – USP and industrial view
  • Bioburden monitoring, USP<1229.3> applies to sterile products
  • USP <1119>
Presentation list:
  • European Regulations
  • USP<1115> Bioburden Control of Non-Sterile Drug Substances and Products
  • Refresher on biofilms including case studies
  • Microbial Control Strategy for Biopharmaceutical Manufacturing
  • Microbial Counts and  Bioburden of Combination Products: Guidelines, Specifics and Case Studies
  • Bioburden for Sterile Operations
  • Bioburden Monitoring, USP<1229.3> applies to Sterile Products, USP <1119>
  • Bioburden Testing of Modern Medicinal Products- Practical Experience of  a Contract Lab
    - Various types of bioburden testing 
    - Technical challenges: Non-Steriles up to ATMP
    - Practical Examples - from classic Pharmaceutical Products to HCT/Ps
  • Minimizing the impact of bioburden and sterility testing on gene therapy batch yield 
  • Assessment of Bioburden Excursions in Non-Sterile Biologics Manufacturing Processes

ECA-Member*: € 1690,-
Non ECA Member*: € 1890,-
EU/GMP Inspectorates*: € 945,-
APIC Member Discount*: € 1790,-

Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.

* auch unkompliziert per Kreditkarte bezahlbar
American Express Visa Mastercard

icon
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
icon
Weitere Termine online
Weitere Termine online nicht verfügbar
icon
Aufzeichnung nicht verfügbar

Haben Sie noch Fragen?

Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.

Frau mit Headset
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de

Zurück

Teilnehmerstimmen - das sagen andere über unsere Seminare:

"Die Umsetzung mit Memberspot ist wirklich ausgezeichnet gelungen.
Es unterstützt die Wissensvermittlung und gewährleistet auch die richtige Durchführung des Kurses.”
Christian Wagener, WAGENER & CO. GmbH
GMP Basis-Einstiegsschulung (B 1) - Aufzeichnung Online Seminar, April 2024

„Danke für das tolle und interessante Seminar! Ich nehme mir fachlich total viel mit und habe viele tolle Menschen kennengelernt.“
Melanie Schifferer, DAIICHI SANKYO EUROPE GmbH
Batch Record Review (QS 23)
September 2024

Guter, breit gefächerter Überblick mit interessanten Verknüpfungen zur Praxis,
welche die Theorie super veranschaulicht.”
Marina Kicoranovic, Labor Hartmann GmbH
GMP/Basis-Einstiegsschulung (B 14), September 2023

Die Referenten waren sehr gut! Sie haben sehr klar gesprochen, nur sehr wenige englische Begriffe
verwendet (super) und waren sehr praxisbezogen.”
Astrid Gießler, Regierungspräsidium Karlsruhe
Live Online Seminar - Basiskurs Computervalidierung & Datenintegrität im GxP Umfeld (B 3), Juni 2023

Sehr guter Bezug zur Schulung für einen GMP-Anfänger. Habe mich sehr gut abgeholt gefühlt.”
Dr. Harald Werner, Infraserv GmbH & Co. Höchst KG
GMP-Basisschulung (B 1), Juni 2023

„Interessante Themen, gut vorgetragen, die eigenen Erfahrungen der Vortragenden helfen, dies noch besser nachzuvollziehen.“ „Gute Gestaltung der Workshops, das Zusammenarbeiten in Gruppen und der Austausch mit anderen hilft sehr.“
Manuela Seibert, Merck, GMP-Leadauditor/in (FA 2), April 2024

NEWSLETTER

Bleiben Sie informiert mit dem GMP Newsletter von Concept Heidelberg!

GMP Newsletter

Concept Heidelberg bietet verschieden GMP Newsletter die Sie auf Ihren Bedarf hin zusammenstellen können.

Hier können Sie sich kostenfrei registrieren.

Kontakt

Kontaktieren Sie uns

Haben Sie Fragen?

Concept Heidelberg GmbH
Rischerstraße 8
69123 Heidelberg

Tel. :+49622184440
Fax : +49 6221 84 44 84
E-Mail: info@concept-heidelberg.de

zum Kontaktformular